Study on AUNIP as a Novel Tumor Marker for Cervical Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Detection of serum AUNIP expression.
- Who it may be relevant to
- Registry conditions: Cervical Cancer. Basic parameters: 20 years — 60 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
To detect the expression of AUNIP in cervical cancer serum, and to clarify its diagnostic and prognostic value.
Detailed description
Blood of all study participants of cervical cancer patients are collected to detect the expression of AUNIP, analyze the statistical correlation between the expression of cervical cancer AUNIP and clinicopathological parameters of patients, and preliminarily understand the expression of AUNIP in cervical cancer tumor tissues and its clinical diagnostic and progniostic value.
Interventions
- Diagnostic test Detection of serum AUNIP expression
The experiment is carried out according to the ELISA kit instructions, and the absorbance optic density (OD) value of the enzyme labeler at 450 nm is read. The protein concentration of AUNIP in the serum sample is calculated according to the standard curve.
Primary outcome measures
- AUNIP expression in serum [Time frame: through study completion, an average of 3 year]
Eligibility criteria
Inclusion criteria
Study group inclusion criteria:
- Women aged 20-60
- There is a definite pathological diagnosis of cervical cancer
Healthy control group:
- Women aged 20-60
- No tumors in the uterus or other parts of the body
- No inflammatory disease
- Blood routine and blood biochemical tests are normal
Exclusion criteria
Exclusion criteria of the study group:
- There are other lesions in the uterus and uterine adnexa
Exclusion criteria of healthy control group:
- Pregnant, lactating or menarche women
- Women who are undergoing human papillomavirus (HPV) vaccination
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Yang Z, Liang X, Fu Y, Liu Y, Zheng L, Liu F, Li T, Yin X, Qiao X, Xu X. Identification of AUNIP as a candidate diagnostic and prognostic biomarker for oral squamous cell carcinoma. EBioMedicine. 2019 Sep;47:44-57. doi: 10.1016/j.ebiom.2019.08.013. Epub 2019 Aug 10. PMID 31409573
- Ma C, Kang W, Yu L, Yang Z, Ding T. AUNIP Expression Is Correlated With Immune Infiltration and Is a Candidate Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma and Lung Adenocarcinoma. Front Oncol. 2020 Dec 9;10:590006. doi: 10.3389/fonc.2020.590006. eCollection 2020. PMID 33363020
Identifiers
NCT: NCT06118463 · yl20231001